US010596255B2 US010596255B2 (ΐ2) United States Patent (ΐο) Patent No.: US 10,596,255 Β2 Clube (45) Date of Patent: *Mar. 24, 2020 (54) SELECTIVELY ALTERING MICROBIOTA 39/0258; C07K 14/315; C07K 14/245; FOR IMMUNE MODULATION C07K 14/285; C07K 14/295; C12N 2310/20; C12N 2320/30 (71) Applicant: SNIPR Technologies Limited, London See application file for complete search history. (GB) (72) Inventor: Jasper Clube, London (GB) (56) References Cited (73) Assignee: SNIPR Technologies Limited, London U.S. PATENT DOCUMENTS (GB) 4,626,504 A 12/1986 Puhler et al. 5,633,154 A 5/1997 Schaefer et al. (*) Notice: Subject to any disclaimer, the term of this 8,241,498 Β2 8/2012 Summer et al. patent is extended or adjusted under 35 8,252,576 Β2 8/2012 Campbell et al. U.S.C. 154(b) by 0 days. 8,906,682 Β2 12/2014 June et al. 8,911,993 Β2 12/2014 June et al. This patent is subject to a terminal dis ­ 8,916,381 Β1 12/2014 June et al. 8,975,071 Β1 3/2015 June et al. claimer. 9,101,584 Β2 8/2015 June et al. 9,102,760 Β2 8/2015 June et al. (21) Appl. No.: 16/389,376 9,102,761 Β2 8/2015 June et al. 9,113,616 Β2 8/2015 MacDonald et al. (22) Filed: Apr. 19, 2019 9,328,156 Β2 5/2016 June et al. 9,464,140 Β2 10/2016 June et al. (65) Prior Publication Data 9,481,728 Β2 11/2016 June et al. 9,499,629 Β2 11/2016 June et al. US 2019/0240326 Α1 Aug. 8, 2019 9,518,123 Β2 12/2016 June et al. 9,540,445 Β2 1/2017 June et al. 9,701,964 Β2 7/2017 Clube et al. (Continued) Related U.S. Application Data (63) Continuation of application No. 16/192,752, filed on FOREIGN PATENT DOCUMENTS Nov. 15, 2018, now Pat. No. 10,363,308, which is a ΕΡ 2 840 140 Α1 2/2015 continuation of application No. 15/820,296, filed on RU 2531343 C2 10/2014 Nov. 21, 2017, now Pat. No. 10,195,273, which is a (Continued) continuation of application No. PCT/EP2017/063593, filed on Jun. 4, 2017. OTHER PUBLICATIONS (30) Foreign Application Priority Data American Lung Association, https://www.lung.org/lung-health-and- Jun. 5, 2016 (GB) .................................... 1609811.3 diseases/lung-disease-lookup/copd/symptoms-causes-risk-factors/ preventing-copd.html, accessed Aug. 5, 2019 (Year: 2019).* (51) Int. Cl. (Continued) Α61Κ 39/00 (2006.01) Α61Κ 39/38 (2006.01) Α61Κ 39/02 (2006.01) Primary Examiner — Gary Β Nickol Α61Κ 39/09 (2006.01) Assistant Examiner — Lakia J Jackson-Tongue Α61Κ 39/085 (2006.01) (74) Attorney, Agent, or Firm — Morrison & Foerster Α61Κ 39/10 (2006.01) LLP Α61Κ 39/08 (2006.01) Α61Κ 39/102 (2006.01) Α61Κ 39/118 (2006.01) (57) ABSTRACT Α61Κ 39/395 (2006.01) Α61Κ 35/15 (2015.01) The invention relates to methods of modulating immune Α6IK 35/17 (2015.01) cells in a patient by altering microbiota of the patient. The Α61Κ 31/7105 (2006.01) invention also relates to methods of modulating treatments Α6 IP 37/00 (2006.01) or therapies in a subject organism by altering microbiota of Α61Ρ 35/00 (2006.01) the subject. The invention also relates to cell populations, U.S. Cl. systems, arrays, cells, RNA, kits and other means for CPC ..... Α61Κ 39/3955 (2013.01); Α61Κ 31/7105 effecting this. In an example, advantageously selective tar- (2013.01); Α61Κ 35/15 (2013.01); Α61Κ 35/17 geting of a particular species in a human gut microbiota (2013.01); Α61Κ 39/0011 (2013.01); Α61Ρ using guided nucleic acid modification is carried out to effect 35/00 (2018.01); Α61Ρ 37/00 (2018.01); Α61Κ the alteration. 2039/505 (2013.01) (58) Field of Classification Search 22 Claims, 19 Drawing Sheets CPC .... Α61Κ 38/00; Α61Κ 39/00; Α61Κ 38/4893; Α61Κ 39/092; Α61Κ 39/099; Α61Κ Specification includes a Sequence Listing. US 10,596,255 Β2 Page 2 (56) References Cited 2018/0273940 Al 9/2018 Clube et al. 2018/0303934 Al 10/2018 Clube et al. U.S. PATENT DOCUMENTS 2018/0326057 Al 11/2018 Clube et al. 2018/0371405 Al 12/2018 Barrangou et al. 9,758,583 Β2 9/2017 Wang et al. 2019/0015441 Al 1/2019 Shachar et al. 9,822,372 Β2 11/2017 Zhang et al. 2019/0021343 Al 1/2019 Barrangou et al. 9,879,269 Β2 1/2018 Barrangou et al. 2019/0134194 Al 5/2019 Clube 10,066,233 Β2 9/2018 Barrangou et al. 2019/0240325 Al 8/2019 Clube et al. 10,136,639 Β2 11/2018 Wuest et al. 2019/0321468 Al 10/2019 Clube et al. 10,136,649 Β2 11/2018 Barrangou et al. 2019/0321469 Al 10/2019 Clube et al. 10,195,273 Β2 2/2019 Clube et al. 2019/0321470 Al 10/2019 Clube et al. 10,300,138 Β2 * 5/2019 Clube ....................... Α61Ρ 37/00 2004/0096974 Al 5/2004 Herron et al. FOREIGN PATENT DOCI 2005/0118719 Al 6/2005 Schmidt et al. 2009/0155768 Al 6/2009 Scholl et al. WO WO-2005/046579 Α2 5/2005 2010/0093617 Al 4/2010 Barrangou et al. WO WO-2005/046579 A3 5/2005 2011/0002889 Al 1/2011 Barrangou et al. WO WO-2007/025097 Α2 3/2007 2013/0011828 Al 1/2013 Barrangou et al. WO WO-2008/108989 Α2 9/2008 2013/0109053 Al 5/2013 MacDonald et al. WO WO-2010/011961 Al 1/2010 2013/0287748 Al 10/2013 June et al. WO WO-2010/075424 Α2 7/2010 2013/0288368 Al 10/2013 June et al. WO WO-2012/079000 Al 6/2012 2013/0309258 Al 10/2013 June et al. WO WO-2012/079000 Α4 6/2012 2014/0068797 Al 3/2014 Doudna et al. WO WO-2012/164565 Al 12/2012 2014/0106449 Al 4/2014 June et al. WO WO-2013/063361 Al 5/2013 2014/0107092 Al 4/2014 Meyerson et al. WO WO-2013/176772 Al 11/2013 2014/0199767 Al 7/2014 Barrangou et al. WO WO-2014/012001 Α2 1/2014 2014/0234972 Al 8/2014 Zhang WO WO-2014/012001 A3 1/2014 2014/0370017 Al 12/2014 June et al. wo WO-2014/018423 Α2 1/2014 2015/0031134 Al 1/2015 Zhang et al. wo WO-2014/093595 Al 6/2014 2015/0050699 Al 2/2015 Siksnys et al. wo WO-2014/093661 Α2 6/2014 2015/0050729 Al 2/2015 June et al. wo WO-2014/093661 A3 6/2014 2015/0064138 Al 3/2015 Lu et al. wo WO-2014/093661 Α9 6/2014 2015/0093822 Al 4/2015 June et al. wo WO-2014/124226 Al 8/2014 2015/0099299 Al 4/2015 June et al. wo WO-2015/034872 Α2 3/2015 2015/0118202 Al 4/2015 June et al. wo WO-2015/058018 Al 4/2015 2015/0125463 Al 5/2015 Cogswell et al. wo WO-2015/069682 Α2 5/2015 2015/0132419 Al 5/2015 Arvik et al. wo WO-2015/071474 Α2 5/2015 2015/0139943 Al 5/2015 Campana et al. wo WO-2015/075688 Al 5/2015 2015/0140001 Al 5/2015 Lee et al. wo WO-2015/088643 Al 6/2015 2015/0184139 Al 7/2015 Zhang et al. wo WO-2015/136541 Α2 9/2015 2015/0290244 Al 10/2015 June et al. wo WO-2015/136541 A3 9/2015 2016/0009805 Al 1/2016 Kowanetz et al. wo WO-2015/148680 Al 10/2015 2016/0024510 Al 1/2016 Bikard et al. wo WO-2015/153940 Al 10/2015 2016/0081314 Al 3/2016 Thurston et al. wo WO-2015/155686 Α2 10/2015 2016/0115488 Al 4/2016 Zhang et al. wo WO-2015/159068 Al 10/2015 2016/0115489 Al 4/2016 Zhang et al. wo WO-2016/044745 Al 3/2016 2016/0130355 Al 5/2016 June et al. wo WO-2016/063263 Α2 4/2016 2016/0159907 Al 6/2016 June et al. wo WO-2016/063263 A3 4/2016 2016/0160186 Al 6/2016 Parsley et al. wo WO-2016/196361 Al 12/2016 2016/0194404 Al 7/2016 June et al. wo WO-2016/196605 Al 12/2016 2016/0208012 Al 7/2016 June et al. wo WO-2016/205276 Al 12/2016 2016/0324938 Al 11/2016 Bikard et al. wo WO-2017/009399 Al 1/2017 2016/0333348 Al 11/2016 Clube et al. wo WO-2017/042347 Al 3/2017 2016/0345578 Al 12/2016 Barrangou et al. wo WO2017058751 Al 4/2017 2016/0347836 Al 12/2016 Grosso wo WO-2017/112620 Al 6/2017 2016/0354416 Al 12/2016 Gajewski et al. wo WO-2017/211753 Al 12/2017 2017/0022499 Al 1/2017 Lu et al. wo WO-2018/064165 Α2 4/2018 2017/0037416 Al 2/2017 Barrangou et al. wo WO-2018/081502 Al 5/2018 2017/0173085 Al 6/2017 Κοvarik et al. wo WO-2018/115519 Al 6/2018 2017/0174713 Al 6/2017 Du et al. wo WO-2018/222969 Al 12/2018 2017/0175142 Al 6/2017 Zhang et al. 2017/0196225 Al 7/2017 Clube et al. 2017/0246221 Al 8/2017 Clube et al. OTHER PUBLICATIONS 2017/0304443 Al 10/2017 Lebwohl et al. 2017/0327582 Al 11/2017 Bissonnette et al.